Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MT-1303 in moderate to severe active Crohn's disease
NL-OMON44387Phase 2Active, not recruiting
- Sponsor
- Tanabe Pharma Europe Ltd
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing MT-1303 with Placebo (2 arms). Primary endpoint: CDAI 100 response at Week 12. Started Sep 2015; status: active, not recruiting.
02
Drugs
amiselimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON44387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44387.